Genetic Heterogeneity of the Precore and the Core Promoter Region of Genotype C Hepatitis B Virus during Lamivudine Therapy

Journal of Medical Virology

Volumn 72, Issue 1, 2004, Pages 26-34

  Kuwahara, Reiichiro ^a   Kumashiro, Ryukichi ^a   Murashima, Shiro ^a   Ogata, Kei ^a   Tanaka, Kazuo ^a   Hisamochi, Akiko ^a   Hino, Teruko ^a   Ide, Tatsuya ^a   Tanaka, Eisuke ^a   Koga, Yuriko ^a   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiviral effect; Chronic hepatitis B; Lamivudine resistant HBV strains; Reversion

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG SENSITIVITY; FEMALE; GENETIC HETEROGENEITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROMOTER REGION; SEROCONVERSION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS MUTANT; WILD TYPE;

ADULT; AGED; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS (GENETICS); PROTEIN PRECURSORS; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; VARIATION (GENETICS);

HEPATITIS B VIRUS;

EID: 10744227810     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10558     Document Type: Article

References (34)

1. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaceadori F, Ferrari C. 1998. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invst 102:968-975.
2. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis MR, McGarvey MJ, Makris A, Thomas HC. 1989. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2:588-591.
3. Cho SW, Hahm KB, Kim JH. 2000. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 32:1163-1169.
4. Chu CJ, Hussain M, Lok AS. 2002. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 122:1756-1762.
5. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. New Engl J Med 333:1657-1661.
6. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. The U.S. Lamivudine Investigator Group. New Engl J Med 341:1256-1263.
7. Dienstag JL, Goldin RN, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. 2003. Histological outcome during long-term lamivudine therapy. Gastroenterology 124:105-107.
8. Gunther S, Meisel H, Reip A, Miska S, Kruger DH, Will H. 1992. Frequent and rapid emergence of mutated pre-C sequence in HBV from e-antigen positive carriers who seroconverted to anti-HBe during interferon treatment. Virology 187:271-279.
9. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. 1981. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 94:744-748.
10. Hoofnagle JH, Peter M, Mullen KD, Mullen KD, Jones DB, Rustgi V, Bisceglie AD, Hallahan C, Park Y, Meschivitz C, Jones EA. 1988. Randomized, controlled trial of recombinant human a-interferon in patients with chronic hepatitis B. Gastroenterology 95:1318-1325.
11. Kanmisango K, Kamogawa C, Sumi M, Goto S, Hirao A, Gonzales F, Yasuda K, Iino S. 1999. Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization assay. J Clin Microbiol 37:310-314.
12. Kao J-H, Chen P-J, Lai M-Y, Lai M-Y, Chen D-S. 2000. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118:554-559.
13. Karasawa T, Aizawa Y, Zeniya M, Kuramoto A, Shirasawa T, Toda G. 1995. Genetic heterogeneity in the precore region of hepatitis B virus in hepatitis B e antigen-negative chronic hepatitis B patient. Spontaneous seroconversion and interferon-induced seroconversion. J Med Virol 45:373-380.
14. Kobayashi S, Shimada K, Suzuki H, Tanikawa K, Sata M. 2000. Development of a new method for detecting a mutation in the gene coding hepatitis B virus reverse transcriptase active site (YMDD motif). Hepatol Res 17:31-42.
15. Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-R, Ng K-Y, Wu P-C, Dent JC, Barber J, Stephenson SL, Gray DF, Asia hepatitis lamivudine study group. 1998. A one-year trial of lamivudine for chronic hepatitis B. New Engl J Med 339:61-68.
16. Lau DT-Y, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. 1997. Long-term follow up of patients with chronic hepatitis B treated with interferon alpha. Gastroenterology 113:1660-1667.
17. Lee WH. 1997. Hepatitis B infection. New Engl J Med 337:1773-1745.
18. Leung NWY, Lai C-L, Chang T-T, Guan R, Lee C-M, Ng K-Y, Lim S-G, Wu P-C, Dent JC, Edmundson S, Condreay LD, Chien R-N, The Asia Hepatitis Lamivudine Study Group. 2001. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 33:1527-1532.
19. Lin S-M, Sheen I-S, Chien R-N, Chu C-M, Liaw Y-F. 1999. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29:971-975.
20. Lok ASF, Chung H-T, Liu VWS, Ma OCK. 1993. Long-term follow-up of chronic hepatitis B patients treated with interferon alpha. Gastroenterology 105:1833-1838.
21. Lok ASF, Akarca U, Greene S. 1994. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci 91:4077-4081.
22. Lok AS-F, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, Benardi M, Andreone P. 2000. Evolution of hepatitis B virus polymerase gene mutation in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 32:1145-1153.
23. Maruyama T, McLachlan A, Iino S, Koike K, Kurokawa K, Milich DR. 1993. The serology of chronic hepatitis B infection revisited. J Clin Invst 91:2586-2595.
24. Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y, Tsuda F, Tanaka T, Miyakawa Y, Mayumi M. 1990. Hepatitis B virus with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 64:1298-1303.
25. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. 1991. Mutation in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. New Engl J Med 324:1669-1704.
26. Orito E, Mizokami M, Sakugawa H, Kojiro M, Ishikawa K, Ichida T, Okanoue T, Yotsuyanagi H, Iino S, The Japan HBV Genotype Research Group. 2001. A case-control study for clinical and molecular biological differences between hepatitis B virus of genotype B and C. Hepatology 33:218-223.
27. Orito E, Ichida T, Sakugawa H, Sata M, Horiike N, Hino K, Okita K, Okanoue T, Iino S, Tanaka E, Suzuki K, Watanabe H, Hige S, Mizokami M. 2001. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34:590-594.
28. Schalm SW, Heathcote J, Cianciara J, Farrelle G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF, International Lamivudine Study Group. 2000. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomized trial. Gut 46:562-568.
29. Schiff E, Karayalcin S, Grimm I, Dienstag J, Husa P, Schalm S, Crowther L, Sullivan M, Woessner M, McPhillips P, Brown N, International Lamivudine Investigator Group. 1998. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy (abstr). Hepatology 28:388A15.
30. Serfaty L, Thabut D, Zoulim F, Andreani T, Chazouilleres O, Carbonell N, Loria A, Poupon R. 2001. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: Result of a pilot study. Hepatology 34:573-577.
31. Song B-C, Suh DJ, Lee HC, Chung Y-H, Lee YS. 2000. Hepatitis B antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32:803-806.
32. Tatulli I, Francavilla R, Rizzo GL, Vinciguerra V, Ierardi E, Amoruso A, Panella C, Francavilla A. 2001. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 35:805-810.
33. Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y, Mayumi M. 1999. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 80:97-112.
34. Yotsuyanagi H, Hino K, Tomita E, Toyoda J, Yasuda K, Iino S. 2002. Precore and core promoter mutations, hepatitis B virus DNA levels, and progressive liver injury in chronic hepatitis B. J Hepatol 37:355-363.